The endothelium, Part I: Multiple functions of the endothelial cells--focus on endothelium-derived vasoactive mediators
M Félétou - 2011 - books.google.com
The endothelium, a monolayer of endothelial cells, constitutes the inner cellular lining of the
blood vessels (arteries, veins and capillaries) and the lymphatic system, and therefore is in …
blood vessels (arteries, veins and capillaries) and the lymphatic system, and therefore is in …
Angiotensin II and vascular damage in hypertension: Role of oxidative stress and sympathetic activation
Reactive oxygen species (ROS) are oxygen derivates and play an active role in vascular
biology. These compounds are generated within the vascular wall, at the level of endothelial …
biology. These compounds are generated within the vascular wall, at the level of endothelial …
[HTML][HTML] Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes
G Passacquale, P Vamadevan, L Pereira, C Hamid… - PloS one, 2011 - journals.plos.org
Background Activated platelets exert a pro-inflammatory action that can be largely ascribed
to their ability to interact with leukocytes and modulate their activity. We hypothesized that …
to their ability to interact with leukocytes and modulate their activity. We hypothesized that …
Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions
A Undas, KE Brummel-Ziedins, KG Mann - Blood, 2007 - ashpublications.org
Aspirin is effective in the prevention of cardiovascular events in high-risk patients. The
primary established effect of aspirin on hemostasis is to impair platelet aggregation via …
primary established effect of aspirin on hemostasis is to impair platelet aggregation via …
Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review
A Rostom, K Muir, C Dubé, E Jolicoeur… - Clinical …, 2007 - Elsevier
Background & Aims: Nonselective non-steroidal anti-inflammatory drugs (NSAIDs) and
cyclooxygenase-2 inhibitors (COX-2s) are used to treat a variety of arthritic and inflammatory …
cyclooxygenase-2 inhibitors (COX-2s) are used to treat a variety of arthritic and inflammatory …
Aspirin resistance and atherothrombotic disease
PJ Mason, AK Jacobs, JE Freedman - Journal of the American College of …, 2005 - jacc.org
Acute coronary syndromes and other manifestations of atherothrombotic disease are
primarily caused by atherosclerotic plaque rupture or fissuring and subsequent occlusive or …
primarily caused by atherosclerotic plaque rupture or fissuring and subsequent occlusive or …
[HTML][HTML] Current and novel antiplatelet therapies for the treatment of cardiovascular diseases
G Jourdi, M Lordkipanidze, A Philippe… - International journal of …, 2021 - mdpi.com
Over the last decades, antiplatelet agents, mainly aspirin and P2Y12 receptor antagonists,
have significantly reduced morbidity and mortality associated with arterial thrombosis. Their …
have significantly reduced morbidity and mortality associated with arterial thrombosis. Their …
A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke
F Cipollone, E Toniato, S Martinotti, M Fazia, A Iezzi… - Jama, 2004 - jamanetwork.com
ContextMyocardial infarction (MI) and ischemic stroke are thought to be caused by matrix
digestion by metalloproteinases (MMPs) leading to rupture of atherosclerotic plaques …
digestion by metalloproteinases (MMPs) leading to rupture of atherosclerotic plaques …
[HTML][HTML] Long-chain acyl-CoA synthetase 4 modulates prostaglandin E2 release from human arterial smooth muscle cells
DL Golej, B Askari, F Kramer, S Barnhart… - Journal of lipid …, 2011 - ASBMB
Long-chain acyl-CoA synthetases (ACSLs) catalyze the thioesterification of long-chain FAs
into their acyl-CoA derivatives. Purified ACSL4 is an arachidonic acid (20: 4)-preferring …
into their acyl-CoA derivatives. Purified ACSL4 is an arachidonic acid (20: 4)-preferring …
Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism
Background—Antagonism or deletion of the receptor (the TP) for the cyclooxygenase (COX)
product thromboxane (Tx) A2, retards atherogenesis in apolipoprotein E knockout (ApoE …
product thromboxane (Tx) A2, retards atherogenesis in apolipoprotein E knockout (ApoE …